Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Investing.com - KBR (NYSE: KBR) reported fourth quarter EPS of $0.69, in line with the analyst estimate of $0.69. Revenue for the quarter came in at $1.73B versus the consensus estimate of $1.78B.
Guidance
KBR sees FY 2024 EPS of $3.10-$3.30 versus the analyst consensus of $3.26.
KBR sees FY 2024 revenue of $7.40B-$7.70B versus the analyst consensus of $7.73B.
KBR's stock price closed at $55.29. It is up 5.78% in the last 3 months and up 0.56% in the last 12 months.
KBR saw 0 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See KBR's stock price’s past reactions to earnings here.
According to InvestingPro, KBR's Financial Health score is "fair performance".
Check out KBR's recent earnings performance, and KBR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar